Discharge During the Weekend After Cardiac Surgery Is Not Associated with Readmissions

According to this new work (soon to be published in Ann Thorac Surg), discharging a patient during the weekend or a holiday after cardiac surgery is not associated with higher rates of readmission compared with patients discharged during weekdays.

El alta en el mismo día luego de una angioplastia coronaria es cada vez más popular pero todavía no es reglaA total of 4877 patients were discharged after cardiac surgery in high-volume sites in the United States. Among them, about 1 every 5 patients was discharged on a Saturday, Sunday, or holiday, and 11.4% had to be readmitted within 30 days.

 

Conversely, 10.9% of the patients who went home on a weekday had to go back to the hospital within the same period of time. The difference between cohorts is not significant.


Read also: Next-Day Discharge after TAVR: Is It Viable?


Discharge is a task that begins immediately after surgery and that must include a patient’s family so that, once s/he gets home, s/he has the necessary resources to meet expectations.

 

Several studies in diverse clinical contexts have shown an increase in the number of events upon admission during the weekend; however, according to this work, going home on a weekend does not entail the same risks.

 

Some comorbidities (older age, chronic obstructive pulmonary disease, dialysis, pleural effusion after surgery, or neurological complications) had previously been associated with more readmissions but were not predictors in this cohort.


Read also: Transradial Access and Early Discharge in Percutaneous Interventions.


Smoking and beta-blocker use were actually associated with more readmissions. However, in the case of beta-blockers, the problem may not lie in their use, but in the fact that they suggest a higher burden of ischemic disease.

 

Original title: Day of Discharge Does Not Impact Hospital Readmission After Major Cardiac Surgery.

Reference: Sanaiha Y et al. Ann Thorac Surg 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....